Genmab A/S PT receives Investment Bank Analyst Rating Update
By Sam BougheddaMorgan Stanley analyst Terence Flynn told investors in a note Friday that Genmab's (NASDAQ:GMAB) announcement of its intent to submit a biologics license...
Denmark-based biotech Genmab (NASDAQ:GMAB) A/S GMAB announced that it has initiated a phase III study evaluating the investigational antibody-drug conjugate tisotumab vedotin as...
Amid the recent declines in broader markets, a blockbuster stock debut has been making headlines: cloud-based data-warehousing firm Snowflake (NYSE:SNOW).While the company priced...
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.